| Literature DB >> 29403749 |
Xiao-Hua Zhang1, Hai-Long Wu1, Jian-Yao Wang1, Yao Chen1, Yong-Jie Yu1, Chong-Chong Nie1, Chao Kang1, De-Zhu Tu1, Ru-Qin Yu1.
Abstract
The effectiveness of traditional Chinese medicine (TCM) against various diseases urges more low cost, speed and sensitive analytical methods for investigating the phamacology of TCM and providing a theoretical basis for clinical use. The potential of second-order calibration method was validated for the quantification of two effective ingredients of Schisandra chinensis in human plasma using spectrofluorimetry. The results obtained in the present study demonstrate the advantages of this strategy for multi-target determination in complex matrices. Although the spectra of the analytes are similar and a large number of interferences also exist, second-order calibration method could predict the accurate concentrations together with reasonable resolution of spectral profiles for analytes of interest owing to its 'second-order advantage'. Moreover, the method presented in this work allows one to simply experimental procedure as well as reduces the use of harmful chemical solvents.Entities:
Keywords: Alternating normalization-weighted error (ANWE) algorithm.; Schizandrin B; Schizandrol A; Second-order calibration; Self-weighted alternating normalized residue fitting (SWANRF) algorithm; Traditional Chinese medicine
Year: 2012 PMID: 29403749 PMCID: PMC5760899 DOI: 10.1016/j.jpha.2012.04.002
Source DB: PubMed Journal: J Pharm Anal ISSN: 2214-0883
Figure 1The chemical structure of Schizandrol A (A) and Schizandrin B (B).
Figure 2The graphical representation of second-order calibration method. EX: excitation spectrum; EM: emission spectrum; C: relative concentration profile.
Figure 3Emission spectrum (A) and fluorescence intensity (B) of Schizandrol A (197 μg/mL) in solvents with different proportions of ethanol and water.
Schizandrol A and Schizandrin B concentrations in calibration set.
| Sample | Sch A (μg/mL) | Sch B (μg/mL) |
|---|---|---|
| 1 | 4.94 | 0.100 |
| 2 | 4.18 | 0.150 |
| 3 | 3.80 | 0.400 |
| 4 | 3.04 | 0.450 |
| 5 | 2.66 | 0.500 |
| 6 | 0.00 | 0.550 |
| 7 | 5.32 | 0.000 |
Analytical results for Schizandrol A and Schizandrin B.
| Sample | Added concentration (μg/mL) | Predicted concentration (μg/mL) | ||||
|---|---|---|---|---|---|---|
| Sch A | Sch B | Sch A | Sch B | |||
| SWANRF | ANWE | SWANRF | ANWE | |||
| P1 | 3.72 | 0.230 | 3.28 (88.3) | 3.56 (95.8) | 0.214 (93.0) | 0.210 (91.1) |
| P2 | 3.34 | 0.240 | 3.13 (93.7) | 3.28 (98.3) | 0.232 (96.6) | 0.238 (99.1) |
| P3 | 2.96 | 0.280 | 2.66 (90.0) | 2.76 (93.3) | 0.255 (91.1) | 0.267 (95.5) |
| P4 | 2.85 | 0.380 | 2.47 (86.8) | 2.66 (93.3) | 0.324 (85.2) | 0.327 (86.0) |
| P5 | 2.47 | 0.390 | 2.28 (92.5) | 2.30 (93.2) | 0.350 (89.6) | 0.368 (94.4) |
| Average recovery (%) | 90.3±2.3 | 94.8±1.8 | 91.1±3.0 | 93.2±3.7 | ||
Recovery in parenthesis.
Figure 4Three-dimensional plots of the excitation–emission matrix fluorescence spectra of (A) Schizandrol A (5.32 μg/mL), (B) Schizandrin B (0.550 μg/mL), (C) plasma-based sample P5 and (D) plasma (diluted 100 times).
Figure 5The resolved spectra of Schizandrol A and Schizandrin B from SWANRF (A1, A2, A3) and ANWE (B1, B2, B3) and the actual spectral profiles.
Statistical validation results for Schizandrol A and Schizandrin B.
| Parameter | Sch A | Sch B | ||
|---|---|---|---|---|
| SWANRF | ANWE | SWANRF | ANWE | |
| SEN*103(mL/μg) | 0.178 | 0.190 | 3.41 | 3.46 |
| SEL | 0.0942 | 0.0903 | 0.142 | 0.145 |
| LOD (ng/mL) | 165 | 199 | 3.20 | 2.90 |
| RMSEP(ng/mL) | 908 | 825 | 112 | 99 |
LOD=3.3 s(0), LOQ=10 s(0), where s(0) is the standard deviation in the predicted concentrations of the target analytes for three different background blank samples.
where d and are the actual and predicted concentrations of the analytes, respectively.